Company Overview and Business Profile

Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical company specializing in the manufacturing and sale of tablets, capsules, and other healthcare products. The company operates its manufacturing unit from Ahmedabad, Sanand, Gujarat, and has established itself as a notable entity in the pharmaceutical manufacturing sector.

Accretion Pharmaceuticals is actively involved in producing and marketing a wide range of pharmaceutical forms, including tablets, capsules, oral liquids, external preparations (such as ointments, creams, gels, lotions, medicated shampoos, mouthwash, and dusting powders), and oral powders (including sachets and dry syrups). The company employs a diversified business model that encompasses both direct sales and contract manufacturing services. In addition to manufacturing products for its own brand, Accretion Pharmaceuticals also produces various pharmaceutical products for other marketers on a loan license or contract manufacturing basis. The company's primary business operations are conducted on a principal-to-principal basis with its diverse range of marketers.

The company has successfully cultivated a strong presence in international markets, with its global footprint extending to over 20 countries, covering regions in Africa, Southeast Asia, and the Middle East. Its clientele is varied, including private institutions, government sectors (both state and central), and reputable pharmaceutical companies, highlighting the breadth of its customer base across public and private sectors.

Financial Performance and Key Metrics

Accretion Pharmaceuticals has exhibited substantial financial growth in recent years. For FY25, the company reports revenue of ₹57.4 Cr and a profit of ₹6.79 Cr. The company's revenue trajectory demonstrates consistent growth; revenue increased by 14.9% from ₹29.53 crores in FY23 to ₹33.94 crores in FY24. Concurrently, its profit after tax saw a significant surge from ₹0.10 crores to ₹3.88 crores during the same period.

For the nine months ending December 31, 2024, the company reported revenue from operations of ₹35.67 crore and a net profit of ₹5.24 crore, indicating strong ongoing growth momentum. The financial performance highlights considerable improvements in profitability margins, with reported PAT margins of 0.35% (FY22), 0.35% (FY23), 11.51% (FY24), and 14.68% (9M-FY25), and Return on Capital Employed (RoCE) margins of 10.49%, 9.87%, 36.73%, and 30.14% respectively for the referenced periods.

Key Financial Highlights:

• Revenue FY24: ₹33.94 crores (14.9% growth Year-on-Year)

• Net Profit FY24: ₹3.88 crores (a significant jump from ₹0.10 crores in FY23)

• Revenue (9 Months FY25): ₹35.67 crores

• Net Profit (9 Months FY25): ₹5.24 crores

• Employee Strength: 105 employees as per recent filings

Market Position and Stock Performance

The market capitalization of Accretion Pharmaceuticals Ltd (ACCPL) stands at ₹71.48 Cr as of July 21, 2025. The stock is traded on the NSE SME platform, with a 52-week high of ₹82.95 and a 52-week low of ₹60. The company's valuation metrics include a Price-to-Earnings (P/E) ratio of 10.53 and a Price-to-Book (P/B) ratio of 13.02.

Promoter holding in Accretion Pharmaceuticals Ltd has decreased to 73.50 per cent as of May 2025, down from 100.00 per cent as of September 2024, reflecting dilution post-IPO listing. The company's operational efficiency has seen notable improvement, with debtor days reducing from 116 to 74.2 days and working capital requirements decreasing from 258 days to 148 days.

IPO Journey and Recent Developments

Accretion Pharmaceuticals successfully completed its Initial Public Offering (IPO) in May 2025. The SME offering, valued at approximately ₹29.75 crore, comprised entirely of a fresh issue of 2.94 million equity shares, with no offer-for-sale (OFS) component. Accretion Pharmaceuticals shares debuted on the exchange at ₹79 per share, representing a discount of ₹22 or 21.78 per cent over the issue price of ₹101 per share.

The IPO for Accretion Pharmaceuticals was subscribed 7.31 times, demonstrating robust investor interest despite the listing discount. The company plans to utilize the proceeds from the public issue for capital expenditure towards the acquisition of new equipment and machinery, capital expenditure for the upgradation of its existing manufacturing facility, repayment or prepayment of certain borrowings, funding of working capital requirements, and for general corporate purposes.

Quality Certifications and Manufacturing Excellence

The company upholds high standards of quality and compliance, evidenced by multiple international certifications. Accretion Pharmaceuticals holds ISO 9001:2015, ISO 14001:2015, and ISO 22000:2005 certifications, underscoring its commitment to quality management and environmental standards. Accretion Pharmaceuticals Limited manufactures high-quality pharmaceutical and nutraceutical products utilizing advanced technology. With a state-of-the-art facility and a team of over 200 professionals, it serves global markets by delivering affordable and effective healthcare solutions.

Industry Position and Competitive Landscape

Accretion Pharmaceuticals Ltd (ACCPL) operates within the Health Care sector, specifically in the Pharmaceuticals sub-sector. Its major competitors include companies like Sakar Healthcare, Lincoln Pharma, and Sotac Pharmaceutical. However, the market capitalization of Accretion Pharma is ₹72 Crores, while the median market capitalization of its peers is ₹694 Crores, indicating the company's relatively smaller scale compared to more established pharmaceutical entities.

The company operates in a highly competitive and fragmented pharmaceutical market, particularly within the contract manufacturing segment. It largely functions on a Business-to-Business (B2B) model, engaging in contract manufacturing which typically involves high volumes but lower margins. Despite this challenging environment, the company has managed to achieve significant growth in recent periods.

Risk Factors and Investment Considerations

While Accretion Pharmaceuticals displays strong recent financial performance, potential investors should consider several factors. The significant boost in top and bottom lines from FY24 onwards warrants scrutiny regarding its sustainability going forward. The FY25 earnings, in particular, raise questions about their long-term viability. The pharmaceutical industry is subject to stringent regulatory challenges, and operating within this highly regulated sector means the company must adhere to numerous compliance requirements. Non-compliance with current or future pharmaceutical regulations could lead to penalties or operational restrictions.

The company has not paid any dividends since its incorporation. It intends to adopt a prudent dividend policy post-listing, based on its financial performance and future prospects.

Accretion Pharmaceuticals represents an emerging player in the pharmaceutical sector, characterized by strong recent growth, a global presence, and recognized quality certifications. However, investors are advised to carefully evaluate the sustainability of recent financial improvements and the inherent competitive dynamics of the pharmaceutical industry.